Obesity and arterial hypertension are important public health problems. Both overweight and hypertension predispose to cardiovascular diseases, such as myocardial infarction, stroke and renal failure. Moreover, overweight clearly predisposes to hypertension, and thus to an increased prevalence of cardiovascular diseases. This in turn favors inactivity and further weight gain, leading to an exacerbation of cardiovascular disorders. Obesity, hypertension and cardiovascular diseases thus contribute to three corners of a vicious triangle. It is within this conceptual framework that this paper reviews the pathogenesis of obesityrelated hypertension, which is highly complex. Many factors act together to promote vasoconstriction and sodium retention. Leptin, free fatty acids and insulin, whose levels are increased in obesity, may act synergistically to stimulate sympathetic activity and vasoconstriction. In addition, obesity-induced insulin resistance and endothelial dysfunction may operate as amplifiers of the vasoconstrictor response. Finally, increased renal tubular reabsorption of sodium may also occur, caused by an increased renal sympathetic nerve activity, the direct effect of insulin, hyperactivity of the renin -angiotensin system and possibly by an alteration of intrarenal physical forces. All together, these factors will lead to sustained hypertension. Because the prevalence of obesity was steadily increasing in the last decades, leading to an increased prevalence of hypertension and cardiovascular disorders, obesity and hypertension will most likely become the health challenges of the twenty-first century.
Introduction
About 45% of deaths in the Western world are related to cardiovascular diseases, mainly due to coronary heart disease, heart failure, stroke and renal failure. Among all cardiovascular risk factors, two major factors emerge today with epidemic proportions and will probably be among the worst killers of the twenty-first century. These are obesity and hypertension.
Obesity is one of the most serious health problems in industrialized societies, with a rapidly increasing prevalence in the USA, 1 in Europe 2 and in the rest of the world. 3 More than a third of the Western population is affected by overweight. Obese subjects are at higher risk of developing cardiovascular diseases and metabolic problems, such as dyslipidemia and diabetes, leading to cardiovascular disorders. Obesity also predisposes to sleep disorders with obstructive sleep apnea, osteoarticular problems, gallbladder disorders and various forms of cancers. Arterial hypertension is an equally important public health problem. More than 20% of the adult population is affected by hypertension and its prevalence clearly increases with age. 4 If untreated for years, hypertension will lead to numerous pathologies, such as myocardial infarction, stroke and renal failure.
In a triangular representation of the three key elements (Figure 1 ), one can understand that obesity and hypertension can favor cardiovascular disorders, but the arrows could have also be drawn the other way around. For example, cardiovascular diseases weaken the heart, tire the cardiac patient and thus lead to inactivity and weight gain. Similarly, cardiovascular-related target-organ damage alters endothelial, vascular and renal functions and thereby worsens arterial hypertension. In addition, obesity per se can lead directly to hypertension. A 'vicious triangle' comes into play, which amplifies the phenomenon. In this review, we will focus on the association between obesity and hypertension and explore the possible mechanisms by which weight gain leads to increased blood pressure.
Obesity is a disease of modern civilization
There is no doubt that obesity qualifies as an obvious civilization disease. Data from the National Health and Nutrition Examination Surveys (NHANES) reveal a steady progression of the prevalence of overweight (body mass index (BMI) > 25 kg=m 2 ) and obesity (BMI > 30 kg=m 2 ) in the last 40 y in the USA. The prevalence of overweight has increased from 43.4% of the adult population (age 20 -74) in the first survey in the early sixties (NHES I, 1960 (NHES I, -1962 to 61% in the last survey of data collected during the late 1990s (NHANES 1999) . Impressively, the prevalence of obesity has more than doubled during the same period, increasing from 12.8% (NHES I) to 26% (NHANES 1999 ). This increase is even more striking among certain groups, such as black or Hispanic women. Europe and the rest of the world have not been spared by this epidemic. In England alone, the prevalence of obesity has tripled from 1980 to 1995 in adults aged 16 to 64.
2 In Switzerland, the national survey conducted in 1997 by the Swiss Office of Statistics 5 has shown an increase in the prevalence of overweight from 30.1 to 34.8% (þ15.6%) and of obesity from 5.3 to 6.8% (þ28%) during the previous 5 y. At this rate of progression, the Swiss values will reach current US values in a matter of 15 y.
The modern world condemns us to become obese. On one hand, our society pushes us to increase energy intake with fat-rich ready-to-eat dinners, passive overeating caused by fatty foods that exert very poor satiety feeling, and refined sugars that lead to hyperglycemia and reactive hyperinsulinemia with appetite-stimulating hypoglycemia. On the other hand, everything incites us to decrease physical activity, from easier transportation means (cars, elevators and escalators) to the omnipresent television that favors inactivity and probably overeating with its frequent commercial interruptions. Overeating of unhealthy foods and inactivity are thus real problems of our civilization. In addition, the progressive aging of our population can only further increase the prevalence of obesity.
Hypertension may also be considered as a disease of modern civilization Several observations provide credibility to this affirmation. First, studies conducted in various so-called 'primitive' populations, such as the Yanomamo Indians in Northern Brazil, 6 report practically no prevalence of hypertension. More interestingly, arterial pressure does not seem to increase with age in those populations, as shown in the study of Bushmen from Botswana 7 or of the Amondava population of the Brazilian Amazon. 8 Physical exercise associated with a nutritional intake with less fat, less sodium, but more vegetables and more complex carbohydrates, could be critical factors. 8 Second, when these 'primitive' populations adopt a Westernized lifestyle, blood pressure rises 9 and the prevalence of obesity and hypertension may increase dramatically. 10 Third, the prevalence of hypertension is usually greater in urban than in rural subjects, an observation that has been made many times in populations as diverse as China, 11 India 12 or Cameroon. 13 Sedentary lifestyle, urban stress and 'unhealthy' nutritional habits seem to play a major role. Finally, obesity increases the risk of developing hypertension, as will be discussed below. Since the prevalence of obesity is increasing steadily, one can reasonably expect an increase in prevalence of arterial hypertension.
The strong link between obesity and hypertension in humans
The association between obesity and hypertension has been recognized for many decades 14, 15 and epidemiological studies show a good correlation between body weight and blood pressure both in normotensive and in hypertensive individuals. 16 Weight gain is an important factor in elevating blood pressure in many essential hypertensive patients 16 and weight loss in obese subjects leads to a decrease in arterial pressure. 17 Interestingly, the association between body weight and arterial pressure is also found in normotensive subjects with a normal body weight, as shown in Figure 2 . The analysis of several thousands individuals 18, 19 has shown that there is a continuous relationship between body mass index (BMI) and systolic or diastolic blood pressure. Thus, weight loss, even within the normal range of BMI between 20 and 25 kg=m 2 , can lower blood pressure, an effect that can be very beneficial in a patient who presents other cardiovascular risks factors. However, one should not conclude that every obese person is hypertensive, but only that weight gain increases the probability of becoming hypertensive, by shifting the distribution frequency of arterial pressure towards higher blood pressure levels. 20 In lean subjects, considering a cut-off value of 140=90 mmHg for defining hypertension, one may find about 80% of normotensive and 20% of hypertensive Figure 1 The concept of the 'vicious triangle' of obesity, hypertension and cardiovascular diseases. Obesity and hypertension predispose to cardiovascular diseases, which in turn favor inactivity and weight gain. In addition, obesity predisposes to hypertension, reinforcing the path to cardiovascular disorders.
From obesity to hypertension J-P Montani et al subjects. However, as one gains weight, the curve shifts to the right and the proportion of hypertensive subjects clearly increases with as many as 50% of obese individuals that suffer from hypertension. 21 It is reasonable to predict that the global obesity epidemic will also lead to a hypertension epidemic.
Numerous mechanisms have been postulated to explain obesity-induced hypertension. However, much of our knowledge is based on correlations between body weight and various factors thought to increase blood pressure (such as insulin levels, plasma renin or sympathetic activity) and the basic physiological mechanisms that link body weight and blood pressure are not yet fully understood. To elucidate these mechanisms, various experimental models of obesity have been developed. However, in most models the obesity is already established at the time of adult age (genetic models) or occurs in small animals (mice and rats) in which extensive cardiovascular studies with invasive monitoring and sequential blood sampling are not always feasible. Of great interest in the pathogenesis of obesity-induced hypertension was the development of experimental models in larger animals in which sequential changes in cardiovascular and endocrine function could be studied during the development of obesity.
Experimental evidence of weight-gain-related hypertension
Wood and Cash developed in 1939 the first experimental model of obesity-induced hypertension in dogs by feeding the animals a high-fat diet. 22 More recently, different laboratories 23 -25 and ourselves 26 have revived the use of this animal model. These studies have shown that weight gain in the dog, induced by a high-fat diet, is associated with an increase in blood pressure, heart rate, cardiac output and glomerular filtration rate. Hyperinsulinemia, elevated plasma renin activity and marked sodium retention are also hallmarks of the model. Furthermore, those dogs showed a progressive alteration in cardiac diastolic function and an impaired response to exercise. 26 Similar findings have been found in rabbits fed a high-fat diet, 27 -29 a model which is well suited for the analysis of sequential changes and the study of the mechanisms of hypertension. As shown in Figure 3 , feeding rabbits a highfat diet (HFD, 10% added fat as 1:1 pork fat:soya oil) ad libitum for 8 weeks led to a progressive increase in body weight (þ47%) and a rapid rise in mean arterial pressure (MAP) and heart rate, that stabilized, respectively, at 14 and 31% greater than control values. 29 The rabbits showed also a net accumulation of sodium, as evidenced by a marked positive daily sodium balance during the first 3 weeks of HFD. At the end of 8 weeks of HFD, fat intake was limited for the next 10 days to avoid further weight gain and to allow us to dissociate the effects of overfeeding with HFD from the effects of obesity per se. Mean arterial pressure and heart rate remained elevated. Thus, time-course analysis of changes in blood pressure may reveal two components of obesityinduced hypertension, an early phase related to HFD and overeating, and a later phase related to weight gain.
Rabbits fed a high-fat diet showed, in comparison to control lean rabbits, a two-fold elevation in plasma insulin despite relatively normal fasting glucose levels (suggestive of insulin resistance), elevated plasma renin activity (þ70%) despite volume retention and hypertension, significant hypertrophy in both the right and left ventricles, 27 and impaired diastolic function. 28 We have also been able to demonstrate that obesity-induced hypertension in rabbits is associated with a non-dipping pattern of blood pressure and heart rate. 30 In fact, obesity appears to change the normal circadian variation of blood pressure in humans as well. Weir et al reported that up to 70% of obese-hypertensive subjects failed to show an appropriate fall in both systolic and diastolic pressure during sleep 31 and it is now well demonstrated that non-dipping of blood pressure is a cardiovascular risk factor. 32 Taken together, these studies demonstrate that weight gain can lead to a sustained increase in blood pressure and they bring new insights in the mechanisms of obesityinduced hypertension. The study of these mechanisms is not only crucial to understand the link between weight gain and elevated blood pressure, but also because the study of obesity-induced hypertension has special relevance to the problem of essential hypertension. In humans, known causes of arterial hypertension account for less than 10% of all hypertensions. 4 In most cases of human hypertension, a precise cause cannot be found and the hypertension is said to be 'essential'. Because many hypertensive subjects are obese and as increased fat seems to explain much of the increase in blood pressure that occurs with aging, obesity could be a major cause of essential hypertension. Thus, a clear understanding of the link between body weight and blood pressure will help us explore the possible causes of human essential hypertension.
Possible mechanisms of obesity-induced hypertension
The pathogenesis of obesity-related hypertension is highly complex and certainly cannot be ascribed to a single gene dysfunction. More likely, many factors act together to promote vasoconstriction and sodium retention. A main hypothesis is that leptin, free fatty acids and insulin, whose levels are increased in obesity, may act individually and synergistically to stimulate sympathetic activity and vasoconstriction. In addition, obesity-induced insulin resistance and endothelial dysfunction may act as amplifiers of the vasoconstrictor response. Finally, increased renal tubular reabsorption of sodium may also occur, caused by an increased renal sympathetic nerve activity, direct effect of insulin, hyperactivity of the renin -angiotensin system and possibly by an alteration of intrarenal physical forces. The complex interaction between all those variables is summarized in Figure 4 .
Elevated sympathetic nervous activity, a common feature of obesity Many lines of evidence suggest that the activity of the sympathetic nervous system is elevated in obesity. First, a correlation between blood pressure and norepinephrine levels has been shown in borderline obese hypertensive subjects and during blood pressure reduction induced by weight loss. 33 The norepinephrine response to stimuli such as upright posture and isometric handgrip may also be elevated in obese subjects. 33, 34 Second, increased energy intake activates the sympathetic nervous system, while fasting reduces sympathetic activity. 35 Third, in healthy humans, body fat is a major determinant of the resting rate of muscle sympathetic nerve discharge 36 and there is a strong correlation between BMI and renal norepinephrine spillover, 37 an index of renal sympathetic activity. Consistent with this hypothesis are the results of studies in dogs 38, 39 and rabbits, 40 which all support the importance of sympathetic activation during rapid weight gain as a plausible mechanism contributing to the increased blood pressure. For example, Rocchini et al 38 found that pretreatment of dogs with clonidine, a centrally active a2-agonist that inhibits central nervous sympathetic activation, prevents insulin resistance and hypertension in HFD-induced obesity. Recently, 40 we administered a combination of a-and b-adrenergic blockers (terazosinþpropranolol) chronically to rabbits, to block the peripheral vasoconstrictor actions and direct renal tubular effects of sympathetic activation, as well as to prevent the sympathetically mediated stimulation of the heart and of renin release (sympathetic clamp). After 2 weeks of adrenergic blockade under control diet, animals were switched to high-fat diet for the following 6 weeks. Pretreatment with a-and b-adrenergic blockers attenuated both the rise in arterial pressure and the sodium retention observed in intact rabbits fed a high-fat diet. In addition, studies in human hypertensives show that obese subjects are more sensitive to a combination of a-and b-blockers than lean blood pressure-matched subjects. 41 Taken together, these results indicate that the activation of the sympathetic nervous system plays an important role in the pathogenesis of obesity-induced hypertension. Several factors can contribute to the activation of the sympathetic nervous system and are listed below.
Role of increased leptin. A key element in the scheme of Figure 4 is leptin, the product of the ob gene. Leptin is constitutively secreted by white adipose cells and its production correlates positively with the percentage of body fat. 42 In turn, leptin acts on the hypothalamus to increase sympathetic activity. 43 In support of the leptin -sympathetichypertension hypothesis, one can quote the following experiments. First, acute leptin infusion in SpragueDawley rats increases sympathetic activity to brown adipose tissue, the kidney, adrenals and hindlimb 44 and chronic leptin infusion increases both blood pressure and heart rate in Sprague -Dawley rats, 45 despite a decrease in food intake that would normally decrease blood pressure. Second, transgenic mice overexpressing mouse leptin 46 with a 10-fold increase in plasma leptin levels show a 17 mmHg increase in systolic blood pressure that was abolished acutely by intraperitoneal injection of an alpha receptor blocker (which did not affect blood pressure in the nontransgenic littermates).
However, leptin also has contrasting counterbalancing cardiovascular effects that may limit its pressor effect. The leptin receptor is expressed on endothelial cells 47 and leptin induces the release of nitric oxide (NO) in rats 48 and in aortic rings. 49 Indeed, leptin evokes an acute hypotensive effect in 6-hydroxydopamine sympathectomized rats. 49 Thus, the influence of leptin on blood pressure homeostasis may be the result of a balance between the pressor action through sympathetic activation and the endothelium-dependent hypotensive effect of leptin. Therefore, any factor that impairs endothelial function in obesity (such as dyslipidemia or insulin resistance) may unmask the pressor effect of leptin.
The fact that many obese humans have high circulating levels of leptin and yet no decrease in appetite raises the possibility that obese subjects become leptin-resistant, ie less sensitive to the effects of leptin. 50 However, leptin resistance may not affect uniformly food intake and sympathoexcitation. There is experimental evidence that Agouti yellow obese mice may show selective leptin resistance, being resistant to the metabolic effects of leptin while maintaining all the sympathoexcitatory effects of leptin. Those mice naturally overexpress the Agouti protein, a protein that inhibits both the melanocortin-1-receptor (the mice become yellow by lack of skin pigmentation) and the melanocortin-4-receptor (the mice become obese because feeding is no longer inhibited). Ten-day restriction of energy intake in Agouti yellow obese mice leads to similar decreases in body weight whether leptin levels are allowed to decrease or are clamped at the initial levels through genetic manipulation, suggesting resistance to the metabolic effects of leptin. Yet, blood pressure decreases markedly in the first case whereas it is maintained in the second case. 46 Furthermore, Agouti yellow obese mice show a much smaller decrease in body weight in comparison to lean Agouti control when leptin is administered chronically. 51 Yet Agouti Figure 4 General scheme of mechanisms of obesity-induced hypertension. A number of factors induced or potentiated by obesity lead to sympathetic activation, vasoconstriction and sodium retention, all promoting hypertension. FFA, free fatty acids; TNF-a, tumor necrosis factor; RAS, renin -angiotensin system; NO, nitric oxide; Ang II, angiotensin II.
From obesity to hypertension J-P Montani et al obese mice show a normal increase in renal sympathetic nerve activity to acute leptin administration 51 and are hypertensive. 52 Further experiments are needed to test whether this concept of selective leptin resistance can be extended to other strains of mice and other species.
Role of elevated free fatty acids (FFA). Another important component in our mechanistic scheme is the role of FFA in obesity-induced hypertension. An increased fat mass may lead to increased lipolysis and higher circulating levels of nonesterified fatty acid, as observed in obese hypertensive patients 53 and in obese dogs. 54 Sympathetic activation may further reinforce the increase in FFA by promoting lipolysis 55 -57 or by decreasing FFA utilization and their re-esterification. 58 There are several postulated mechanisms by which FFA may elevate arterial pressure. 61 FFA may also lead to insulin resistance, 62 as discussed below. Interestingly, clonidine, a drug that prevents insulin resistance and hypertension in obese dogs, 38 is also known to suppress FFA levels. 63 In addition, FFA may interact with the sympathetic nervous system (SNS). Administration of FFA in normotensive subjects enhances venoconstrictor response to phenylephrine, but not to angiotensin, and obese subjects with elevated blood pressure show increased forearm vascular a-adrenergic tone and reactivity, 64 suggesting that there may be an increased vascular reactivity in obesity mediated by elevated plasma FFA concentrations that is specific for aadrenergic activation. Fatty acids may finally activate the SNS through direct actions on the vasomotor centers of the brain or indirectly through afferent pathways originating in the liver. Grekin et al have shown that an acute infusion of oleate, a long chain FFA, into the portal vein increased blood pressure in rats. This effect was abolished by adrenergic blockade. 65 Moreover, chronic portal venous infusion of oleate or linoleate for 7 days leads to a sustained increase in arterial pressure and heart rate. 65 Role of hyperinsulinemia and insulin resistance. An intriguing aspect is the place of hyperinsulinemia and insulin resistance in the general scheme of the mechanisms of obesity-induced hypertension. One classical hypothesis is that hyperinsulinemia, which is common in obesity and occurs in compensation for insulin resistance, causes hypertension through central nervous system actions that lead to increased sympathetic activity. 66 Indeed, acute studies have shown that hyperinsulinemia increases muscle sympathetic nerve activity in humans 67 and a good correlation has been found between insulin levels and blood pressure in both normotensive and hypertensive patients. 68 Insulin may also act directly on the kidney to promote sodium retention. 69 The causes of insulin resistance, which is defined as a state of reduced responsiveness to normal circulating concentrations of insulin, 70 are complex and may include various components. 71, 72 Further complexity is given by the fact that insulin resistance may affect various target organs, such as skeletal muscle, liver, adipocytes, vascular smooth muscle cells and endothelial cells, via different mechanisms. Two candidate substances may play a major role in obesityrelated insulin resistance, FFA and tumor necrosis factor alpha (TNF-a).
FFA and insulin resistance. Since Randle proposed in the 1960s the intracellular mechanism by which elevated FFA concentrations lead to decreased glucose uptake, 73, 74 a number of studies addressed this issue and elucidated it in more details. Randle suggested that fat-induced increase in intramitochondrial acetyl CoA and NADH through a sequence of regulatory interactions leads to an inhibition of phosphofructokinase and hexokinase II resulting in an increase of intracellular glucose concentration and decreased glucose uptake. 75 -77 Shulman and his group challenged that view. They suggested that fatty acid-induced inhibition of glucose transport or phosphorylation activity precedes the reduction in muscle glycogen synthesis and glucose oxidation. 78 Increasing intracellular fatty acid metabolites may activate serine=threonine kinase cascade, possibly through the protein kinase C y, 62, 79 leading to serine= threonine phosphorylation of IRS-1 (insulin receptor substrate 1). Serine phosphorylated form of IRS-1 does not bind nor activate phosphatidylinositol (PI) 3-kinase, resulting in decreased glucose transport and other manifestations of insulin resistance. 72 FFA may as well influence directly GLUT4 transporter expression, transcription 80 or its cell surface recruitment. 81 In addition, FFA reduce hepatic insulin clearance 82 -84 and enhance hepatic glucose production 85 which both potentiate the effects of insulin resistance.
TNF-a and insulin resistance. TNF-a is another candidate possibly responsible for the induction of insulin resistance in obesity. It is produced by adipocytes and increased in the adipose tissue of obese rodents 86 as well as in humans. 87 Hotamisligil's team and other groups demonstrated that TNF-a treatment leads to a reduction of insulin-stimulated insulin receptor autophosphorylation and subsequent inhibition of IRS-1 phosphorylation. 88 -91 Additionally, TNF-a induces IRS-1 modification by serine phosphorylation, 90, 92 which renders this molecule inhibitory for the signaling capacity of the insulin receptor. Supportive data for the role of TNF-a in insulin resistance come also from in vivo studies. Neutralization of TNF-a effects in obese rats resulted in increased insulin sensitivity 86, 93 while TNF-a 7=7 mice remained insulin sensitive when put on high-fat diet. 94 In addition, insulin resistance could also be a consequence, and not just a cause of sympathetic activation. 95 For example, it is known that epinephrine leads to both peripheral and hepatic resistance to the action of insulin. 96 A reflex increase in sympathetic tone in normotensive subjects can also lead to acute insulin resistance in the forearm. 97 Finally, clonidine, a drug that inhibits sympathetic outflow, improves insulin sensitivity in hypertensive patients with type 2 diabetes 98 and prevents insulin resistance in dogs fed a high-fat diet without affecting weight gain. 38 Whatever the mechanisms of insulin resistance, the cardiovascular consequences are serious: hyperinsulinemia and decreased vascular relaxation capabilities. Endothelial insulin resistance may impair NO-mediated vasodilatory action of insulin 99, 100 and may thus blunt the direct hypotensive effect of insulin. Note also that, although fasting glucose levels are often normal in obese subjects, glucose intolerance with higher post-prandial hyperglycemic peaks is quite common, 101 in relation with insulin resistance. Glucose levels between 11 and 16 mmol=l, not uncommon in the post-prandial state of obese subjects, could be sufficiently elevated to attenuate insulin-mediated NO release by endothelial cells. 102 Additional factors promoting sympathetic activation. A number of other factors may also contribute to the increased sympathetic activity of obesity. First, obstructive sleep apnea is more common among obese people, 103 probably in relation to the increased fat mass in the upper airway region. 104 This syndrome is characterized by frequent nocturnal apneas that lead to repetitive hemoglobin desaturation, chemoreceptor activation and sympathetic stimulation. Interestingly, sympathetic activation remains high also during the daytime. 105, 106 Second, endothelial dysfunction caused by insulin resistance and=or elevated FFA may also lead to sympathetic activation at various levels. When endothelial function is normal, endothelial-derived NO diffuses easily to the adjacent adrenergic varicosities, inhibiting the release of norepinephrine. 107 Increased NO release in certain areas of the brain involved in sympathetic control such as organum vasculosum laminae terminalis (OVLT), 108 paraventricular nucleus of the hypothalamus (PVN) 109 or rostral ventrolateral medulla (RVLM), 110 leads to a decreased sympathetic outflow. Although NO in those areas is produced mainly by neurons and glial cells, the contributory role of endothelium-derived NO in the central nervous system cannot be excluded. One can thus understand that endothelial dysfunction, which leads to an inappropriate low NO release, may no longer suppress sympathetic activity in certain circumstances.
Abnormal renal sodium handling
Obese patients have elevated renal blood flow and glomerular filtration rate (GFR), and yet they show a delayed urinary sodium excretion in response to a saline load, 111 a finding also encountered in obese dogs. 112 Furthermore, in dogs 25 and rabbits 40 fed a high salt diet, there is marked renal sodium retention despite an elevated GFR and the lack of renal vasoconstriction during weight gain. More likely, renal sodium retention is due to a primary increase in tubular reabsorption. If this increase occurs at a site proximal to the macula densa, this would result in a compensatory increase in GFR. The increase in tubular reabsorption can be caused by multiple mechanisms as depicted in the scheme of Figure 4 .
First, increased renal sympathetic nerve activity promotes tubular reabsorption both by a direct action on proximal and distal tubules 113 and indirectly via stimulation of renin release and angiotensin-aldosterone production. In dogs fed a high-fat diet, renal nerves appear to play a key role in the sodium retention associated with weight gain, since dogs with intact renal nerves retain almost twice as much sodium as the bilaterally renal-denervated dogs. 39 Second, activation of the renin angiotensin system is very common in obese subjects, despite elevated blood pressure, marked sodium retention and increased extracellular fluid volume. 114 An elevation in plasma renin activity (PRA) is seen steadily in dogs 25 and rabbits 27 fed a high-fat diet. The exact cause of elevated angiotensin levels is not clear, but activation of renal sympathetic nerves certainly seem to play a contributory role since bilaterally-denervated dogs fed a high fat diet exhibit a marked attenuation of the increase in PRA seen in dogs with intact renal nerves. 39 Another source of circulating angiotensin II could be the increased fat mass. Adipocytes, which contain all the elements of the reninangiotensin system, can release both angiotensinogen and angiotensin II, and could thus contribute to an elevation in plasma angiotensin levels. 115 Third, obese subjects may have decreased circulating atrial natriuretic peptide (ANP) levels both at the basal level and in response to salt-loading. This could be explained by a greater gene expression of the peptide clearance receptor (NPr-C) in adipose tissues of obese hypertensive. 116 Fourth, hyperinsulinemia of obesity may promote sodium retention by a direct action on the kidney, 69 both on proximal and on distal tubules. 117 Interestingly, large elevations in plasma glucose (25 mmol=l) that normally completely blunt insulin-mediated NO release by endothelial cells do not alter the increase in sodium transport induced by insulin in A6 cells, a model of the distal tubule. 102 If these observations can be extended to other factors causing insulin resistance, it would appear that insulin resistance might not affect insulin-mediated sodium retention whereas it clearly impairs endothelial function. In obesity, the vasodilatory effects of insulin would thus be blunted whereas the sodium-retaining properties of insulin would be well maintained. Both would contribute to hypertension.
Finally, an alteration of intrarenal physical forces may contribute to the increased tubular reabsorption seen in obesity. Kidneys from obese animals and humans are encapsulated tightly with fat which may penetrate the renal hilum into the sinuses surrounding the renal medulla. 118 In addition, histological changes in the renal medulla may occur with an increase in extracellular matrix and in the number of interstitial cells. 118 Those changes may elevate renal interstitial fluid hydrostatic pressure, as documented by Hall et al 118 in obese dogs. In turn, this reduces vasa recta blood flow and may partially compress the loop of Henle, slowing down tubular flow rate. All together, these effects would increase sodium reabsorption in the loop of Henle.
Conclusions and perspectives
Cardiovascular diseases are the number one killer in the Western world, representing about 45% of all causes of mortality. Among all cardiovascular risk factors, obesity and hypertension emerge today with epidemic proportions. On the one hand, obesity predisposes to heart failure and other cardiovascular problems, which in turn favor inactivity and further weight gain. On the other hand, untreated hypertension leads to target organ damage, which in turn may worsen the initial hypertension. Since weight gain clearly predisposes to hypertension, the steadily increasing prevalence of obesity in the last few decades will lead to a vicious circle of cardiovascular-related problems. Obesity and hypertension may thus become the worst killers of the twenty-first century.
The pathogenesis of obesity-related hypertension is complex. Many factors act together to promote vasoconstriction and sodium retention. Increased levels of leptin, free fatty acids and insulin may stimulate the activity of the sympathetic nervous system and may thus play a pivotal role in linking obesity to hypertension. In addition, obesityinduced insulin resistance and endothelial dysfunction may act as amplifiers of the vasoconstrictor response. Finally, abnormal sodium handling by the kidney may further promote hypertension. A better understanding of these mechanisms may lead to a better control and treatment of cardiovascular disorders.
